

CURRICULUM VITAE (12/18/2003)
Peter G. Rose, M.D.

DATE OF BIRTH March 11, 1955

PLACE OF BIRTH Beverly, Massachusetts

SOCIAL SECURITY NUMBER Upon Request

OFFICE ADDRESS Division of Gynecologic Oncology
MetroHealth Medical Center
Cancer Care Center, Suite 2017
Case Western Reserve University
2500 MetroHealth Drive
Cleveland, OH 44109
Phone (216) 778-5885
Fax (216) 778-4741

ACADEMIC APPOINTMENTS

Case Western Reserve University
School of Medicine, Cleveland, OH
Department of Reproductive Biology & Oncology
Professor with Tenure 7/1/99 – present
Associate Professor 12/92 –7/1/99

University of Massachusetts
School of Medicine, Worcester, MA
Department of Obstetrics & Gynecology
Associate Professor 7/91-11/92
Assistant Professor 7/88-7/91

State University of New York at Buffalo
School of Medicine, Buffalo, NY
Instructor of Obstetrics & Gynecology 7/86-6/88

The Ohio State University
School of Medicine, Columbus, OH
Instructor of Obstetrics & Gynecology 7/83-6/86

HOSPITAL APPOINTMENTS

MetroHealth Medical Center
Cancer Care Center
Cleveland, OH
Director of Gynecologic Oncology 2/2002-present
Chairman-Patrick Catalano, MD

Hillcrest Hospital
Mayfield Heights, OH
Director of Gynecologic Oncology 2/2002 – present

MacDonald Women's Hospital
University Hospitals of Cleveland
Director of Gynecologic Oncology 2/94-2/2002
Co-Director of Gynecologic Oncology 12/92-2/94
Chairman – Wulf Utian, MD, PhD 12/92-12/99

Mt. Sinai Medical Center
Cleveland, OH
Gynecologic Oncologist 12/92-2/2000

University of Massachusetts Medical Center
Director of Gynecologic Oncology 7/88-11/92
Chairman – Richard Hunter, M.D. Kenneth Noller, MD

Medical Center of Central Massachusetts
Worcester, MA
Gynecologic Oncologist 7/88-11/92

St. Vincent Hospital
Worcester, MA
Gynecologic Oncologist 7/88-11/92

PREVIOUS TRAINING

Roswell Park Memorial Institute 7/86-6/88
Fellow in Gynecologic Oncology
Chief – M. Steven Piver, MD

The Ohio State University 7/83-6/86
Resident in the Department of Obstetrics & Gynecology
Chairman – Frederick P. Zuspan, MD

Vanderbilt University 7/81-7/83
Resident in the Department of Surgery
Chairman – John L. Sawyers, MD

MEDICAL SCHOOL

Boston University School of Medicine 1979-1981
Medical Doctor
Boston, MA

St. Louis University School of Medicine 1977-1979
St. Louis, MO

COLLEGE

The University of Connecticut
Biochemistry and Biophysics 1973-1977
BS Magna Cum Laude
Storrs, CT

MEDICAL LICENSE

Ohio Medical License #49163
Massachusetts Medical License #59295
New York Medical License # 165301-1

EXAMINATIONS

National Board Examinations I, II & III
American Board of Obstetrics & Gynecology (ABOG)
Written Board 1986
Oral Board 1989
Re-certification until 2002

ABOG Division of Gynecologic Oncology
Written Board 1989
Oral Board 1990
Re-certification until 2002

ADDITIONAL TRAINING

American Cancer Society Clinical
Fellowships 1986-1987, 1987-1988

Galloway Fellow 1984
Memorial Sloan Kettering Cancer Center
New York, NY
Chairman – John L. Lewis, Jr., MD

Laser Certification, 1984
Grant Hospital, Columbus, OH

Laser Certification, 1988
Roswell Park Memorial Institute
Buffalo, NY

American Cancer Society Clinical Grant
1978 Gynecologic and Urologic Cancers

ORGANIZATIONS

American College of Obstetrics & Gynecology
Jr Fellow 1983, Fellow 1990

American Society of Clinical Oncology
(Member 1989)

Society of Gynecologic Oncologists

Candidate Member 1989, Member 1992
Member Education Committee 1994-1997,
Editor of SGO Issues 1995-1998,
Member of the Communications Committee
(1996-1997)
Member of the Coding Committee
(1999-current)
Member of the Program Committee 2001

New England Association of Gynecologic Oncologists
(Candidate Member 1989, Member 1992-current)

New England Cancer Society 1991-1992

American College of Surgeons
(Fellow 1992-1998)

Gynecologic Oncology Group
Principal Investigator (PI):
2/90-11/92, 2/95-7/02
Affiliate PI 11/92-2/95, 7/02-current
Member Developmental Therapeutics Committee 1/96-
current (Section Head Cervical Cancer 1/03)
Member Phase I Committee 1/97-current
Member Ovarian Committee 1/98-current

HONORS

Phi Beta Kappa
Honors College
The University of Connecticut

Faculty Teaching Award 1991
Department of Obstetrics & Gynecology
University of Massachusetts

Faculty Teaching Award 1994
Department of Obstetrics & Gynecology
Mt. Sinai Hospital, Cleveland, OH

Association of Professors of Obstetrics and Gynecology
(APGO)
Medical Student Teaching Award 1998
Department of Obstetrics & Gynecology
University Hospitals of Cleveland

Cleveland Magazine: Best Doctors 1998, 2002

Council on Residency Education in Obstetrics and
Gynecology (CREOG)
Resident Teaching Award 2000
Department of Obstetrics & Gynecology
University Hospitals of Cleveland

TEACHING RESPONSIBILITIES

Member of the Department of Obstetrics & Gynecology
Education Committee U-MASS (1988-11/92)

Coordinator of Core Resident Lecture Series in
Gynecologic Oncology
(6 month block 1989, 1991, 1993, 1995, 1997, 1999,
2001)

Second Year Medical Student Lecture and Lab
(1988-11/92, 1994-current)

Third Year Medical Student Clinical Core Rotation and
Weekly Lectures in Gynecologic Oncology
(1988-11/92, 12/92-current)

Coordinator of Fourth Year Elective in Gynecologic
Oncology
(1988-11/92, 1/94-current)

Grand Rounds at area hospitals

ADMINISTRATIVE RESPONSIBILITIES

MetroHealth Medical Center

Development Committee Womens Inpatient Unit
2002-current

Departmental Committee on Adjunct Clinicians:
Responsibilities and Credentialing 2002-current

University Hospitals of Cleveland

Operating Room Committee 1993-2002

Clinical Trials Development & Review Committee 1992-
2002

Invasive Procedures Monitoring Committee 1993-1994

Infectious Disease Committee 11/92-2002

Ireland Cancer Center Committee 1/94-2002

Ireland Cancer Center Marketing Committee 1/94-2002

Credentialing Committee Department of Obstetrics &
Gynecology Member 1/94-2002, Chair 1999-2002

Department of Reproductive Biology Promotions and
Tenure Member 1999, Chair 2000

University of Massachusetts Medical Center

Cancer Committee 1988-1992

Quality Assurance 1988-1989

Operating Room Committee 1991-1992

Medical Records Committee 1991-1992

Ob/Gyn Marketing Committee

Director 1992

Saint Vincent's Hospital

Cancer Committee 1988-1992

**CLINICAL RESEARCH
Cooperative Studies**

Principal Investigator:
Gynecologic Oncology Group
2/90-11/92, 2/95-current

Study Chairman:
Gynecologic Oncology Group – 26LL
Phase II trial of prolonged oral etoposide (VP-16) in patients with advanced pelvic malignancies.

Study Chairman:
Gynecologic Oncology Group – 120
A randomized comparison of 5-FU infusion and bolus cisplatin versus weekly cisplatin as adjunct to radiation therapy in patients with stage IIB, III, IVA carcinoma of the cervix and negative para-aortic nodes.

Study Chairman:
Gynecologic Oncology Group – 127D
A phase II study of hexamethylmelamine in advanced or recurrent squamous cell carcinoma of the cervix.

Study Chairman:
Gynecologic Oncology Group – 129B
Phase II trial of prolonged oral etoposide (VP-16) in the treatment of recurrent or advanced endometrial carcinoma.

Study Chairman:
Gynecologic Oncology Group – 131B
Phase II trial of prolonged oral etoposide (VP-16) in the treatment of recurrent or advanced leiomyosarcoma of the uterus.

Study Chairman:
Gynecologic Oncology Group – 152
A phase III randomized study of cisplatin (NSC #119875) and paclitaxel (NSC #125973) with interval secondary cytoreduction versus cisplatin and paclitaxel in patients with suboptimal stage III and IV epithelial ovarian carcinoma.

Study Chairman:
Gynecologic Oncology Group – 127H
Phase II trial of prolonged oral etoposide (VP-16) in persistent or recurrent squamous cell carcinoma of the cervix.

**CLINICAL RESEARCH
Cooperative Studies (Con't)**

Study Chairman:

Gynecologic Oncology Group – 76X

Phase II trial of cisplatin and paclitaxel in the treatment of recurrent or advanced squamous cell carcinoma of the cervix.

Study Chairman:

Gynecologic Oncology Group – 9603

A Phase I trial of paclitaxel, carboplatin and increasing doses of prolonged oral etoposide in untreated ovarian, peritoneal and tubal carcinoma.

Study Chairman:

Gynecologic Oncology Group – 168

Phase II study of anastrozole (Arimidex) in advanced, recurrent or persistent endometrial cancer.

Study Chairman:

Gynecologic Oncology Group – 9704

A Phase I study of liposomal doxorubicin (Doxil) and prolonged oral etoposide as second line therapy in ovarian and peritoneal carcinoma.

Study Chairman:

Gynecologic Oncology Group – 9703

A Phase I study of paclitaxel, carboplatin, and an increasing dose of liposomal doxorubicin (Doxil) as primary therapy in ovarian, peritoneal and tubal carcinoma.

Study Chairman:

Gynecologic Oncology Group – 9807

A Phase I study of sequential prolonged oral topotecan and prolonged oral etoposide as second line therapy in ovarian and peritoneal carcinoma.

Study Chairman:

Gynecologic Oncology Group – 126J

A Phase II study of docetaxel in paclitaxel resistant ovarian carcinoma.

Study Chairman:

Gynecologic Oncology Group – 127R

Approved pending activation

A Phase II study of liposomal doxorubicin (Doxil) as second line therapy in squamous cell carcinoma of the cervix.

**CLINICAL RESEARCH
Cooperative Studies (Con't)**

Study Chairman:
Gynecologic Oncology Group –
Approved pending activation
A Phase I/II study of whole pelvic radiation therapy with concomitant cisplatin and oral topotecan chemotherapy in patients with cervical carcinoma (stages I-IV) limited to the pelvis.

Study Chairman:
Gynecologic Oncology Group –9913
Approved pending activation
A Phase I/II study of extended field radiation therapy with concomitant cisplatin and oral topotecan chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes.

Study Chairman:
Gynecologic Oncology Group –9912
Approved pending activation
A Phase I/II study of whole pelvic radiation therapy with concomitant cisplatin and gemcitabine chemotherapy in patients with cervical carcinoma (stages I-IV) limited to the pelvis.

Study Chairman:
Gynecologic Oncology Group –
Approved pending activation
A Phase I/II study of extended field radiation therapy with concomitant cisplatin and gemcitabine chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes.

Study Chairman:
Gynecologic Oncology Group
Approved pending activation
A Phase II study of prolonged oral topotecan as second line therapy in ovarian and peritoneal carcinoma.

Study Chairman:
Gynecologic Oncology Group
Approved pending activation
A Phase II study of sequential oral topotecan and oral etoposide as second line therapy in ovarian and peritoneal carcinoma.

Study Chairman:
SmithKline Beecham Pharmaceuticals
A Phase I study of oral topotecan and liposomal doxorubicin (Doxil) as second line therapy in ovarian, peritoneal and tubal carcinoma.

**CLINICAL RESEARCH
(Con't)**

Study Chairman:
SmithKline Beecham Pharmaceuticals
A Phase I/II study of carboplatin and topotecan as second line therapy in platinum sensitive ovarian or peritoneal carcinoma.

Study Chairman:
Bristol-Myers Squibb Pharmaceuticals
A Phase II study of weekly paclitaxel and carboplatin as second line therapy in platinum sensitive ovarian or peritoneal carcinoma.

Study Chairman:
Ortho Biotech Pharmaceuticals
A Phase I trial of liposomal doxorubicin and vinorelbine in recurrent ovarian or peritoneal cancer.

Study Chairman:
AstraZeneca Pharmaceuticals
A Phase II Study of Anastrozole (Arimidex®) in Recurrent or Persistent Progesterone Receptor or Progesterone Sensitive Endometrial Cancer .

Study Chairman:
Eli Lilly & Company
A phase II randomized study of gemcitabine and carboplatin utilizing two different dose schedules in patients with recurrent ovarian or peritoneal carcinoma.

Study Chairman:
OrthoBiotech
A phase II trial of Doxil and carboplatin in advanced and recurrent endometrial carcinoma

Study Chairman:
OrthoBiotech
A phase II trial of Doxil, carboplat and paclitaxel with G-CSF in advanced and recurrent endometrial carcinoma

Study Chairman:
Ireland Cancer Center
Phase II study of weekly 72 hour infusion of topotecan in patients with advanced ovarian carcinoma.

Study Chairman:
Ireland Cancer Center
Study of PET for evaluating disease status before second look laparotomy in patients with ovarian carcinoma.

**CLINICAL RESEARCH
Cooperative Studies (Con't)**

Study Chairman:
Ireland Cancer Center
Evaluation of PET scanning for determining para-aortic nodal disease status prior to surgical staging in patients with advanced cervical carcinoma.

Investigator:
U.S. Bioscience
A Phase III randomization study of Cyclophosphamide and cisplatin with or without pretreatment with WR-2721 in patients with stage III or stage IV epithelial ovarian carcinoma.

Investigator:
Pharmacia & Upjohn
A Phase I study of intraperitoneal immunotoxin therapy for cancer using a recombinant Ricin A chain conjugated to 454A12.

Investigator:
Pharmacia Upjohn
A Phase II Trial of Carboplatin/paclitaxel/CPT-11 in patients with ovarian cancer, primary carcinoma of the peritoneum, or fallopian tube cancer.

Investigator:
Organon
A randomized multicenter placebo-controlled dose findings/efficacy/safety study ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in patients with ovarian cancer.

Investigator:
Sequus Pharmaceuticals
Non-comparative multicenter study of Doxil in the treatment of patients with epithelial ovarian cancer.

Investigator:
Biochem Pharmaceuticals
A phase II study of VX-710 plus paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy with or without cisplatin.

GRANTS

Agency:	American Cancer Society
Title:	Pilot Study Grant
Project Period:	5/14/2001- present
Project Amount:	\$9,185.00
Agency:	National Cancer Institute
Title:	Gynecologic Oncology Group Case Western Reserve University
Project Period:	1/1/1993-7/1/2002
Project Amount:	\$619,886.00
Agency:	National Cancer Institute
Title:	Gynecologic Oncology Group The University of Massachusetts Medical Center
Project Period:	1/1/1990-6/30/1992
Project Amount:	\$87,835.00
Agency:	American Cancer Society
Title:	Clinical Fellowship
Project Period:	7/1/1986-6/30/1988
Project Amount:	\$12,000.00
Agency:	American Cancer Society
Title:	Clinical Fellowship
Project Period:	1978
Project Amount:	\$1,000.00
Agency:	U.S. Bioscience
Title:	A Phase III randomization study of cyclophosphamide and cisplatin with/ without pretreatment with WR-2721 in patients with stage III or IV epithelial ovarian carcinoma
Project Period:	2/1/1989-6/30/1992
Project Amount:	\$70,000.00
Agency:	Cetus Corporation
Title:	Phase I study of intraperitoneal immunotoxin therapy for cancer using recombinant Ricin A chain conjugated to antibody 454A12
Project Period:	1989
Project Amount:	\$1,000.00
Agency:	Organon, Inc.
Title:	A randomized multicenter placebo-controlled dose finding/efficacy/safety study ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in patients with ovarian cancer
Project Period:	2/1/1992-2/1/1993
Project Amount:	\$36,000.00

GRANTS (Con't)

Agency:	Organon, Inc.
Title:	A randomized multicenter placebo-controlled dose finding/efficacy/safety study ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in patients with ovarian cancer
Project Period:	2/1/1993-8/5/1993
Project Amount:	\$12,000.00
Agency:	Department of Reproductive Biology CWRU
Title:	IGF Expression and modulation in ovarian cancer
Project Period:	7/1/1993-7/1/1994
Project Amount:	\$15,000.00
Agency:	Sequus Pharmaceuticals, Inc.
Title:	Noncomparative multicenter study of Doxil in the treatment of patients with epithelial ovarian cancer
Project Period:	10/1/1996-10/1/1998
Project Amount:	\$45,500.00
Agency:	Biochem Pharmaceuticals
Title:	A Phase II study of VX-710 plus paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy with or without cisplatin
Project Period:	1/1/1999-5/4/2000
Project Amount:	\$16,725.00
Agency:	SmithKline Beecham Pharmaceuticals
Title:	A Phase I study of oral topotecan and liposomal doxorubicin (Doxil) as second line therapy in ovarian, peritoneal and tubal carcinoma
Project Period:	12/15/1999-current
Project Amount:	\$50,000.00
Agency:	SmithKline Beecham Pharmaceuticals
Title:	A Phase I/II study of carboplatin and topotecan as second line therapy in platinum sensitive ovarian or peritoneal carcinoma
Project Period:	5/15/2000-current
Project Amount:	\$60,000.00
Agency:	Bristol Myers Squibb
Title:	A Phase II study of weekly paclitaxel and carboplatin as second line therapy in platinum sensitive ovarian or peritoneal carcinoma.
Project Period:	5/15/2000-current
Project Amount:	\$85,000.00

GRANTS (Con't)

Agency:	AstraZeneca
Title:	A Phase II study of Anastrozole (Arimidex®) in recurrent or persistent progesterone receptor or progesterone sensitive endometrial cancer.
Project Period:	8/15/2000-current
Project Amount:	110,000.00
Agency:	Pharmacia & Upjohn
Title:	A Phase II trial of carboplatin/paclitaxel/CPT-11 in patients with ovarian cancer, primary carcinoma of the peritoneum, or fallopian tube cancer.
Project Period:	9/1/2000-12/1/2001
Project Amount:	\$17,500.00
Agency:	OrthoBiotech
Title:	A Phase I study of liposomal doxorubicin (Doxil) and vinorelbine as second line therapy in ovarian, peritoneal and tubal carcinoma.
Project Period:	5/2001 –current
Project Amount:	\$50,000.00
Agency:	Eli Lilly and Company
Title:	A Phase II randomized study of gemcitabine and carboplatin utilizing two different dose schedule in patients with recurrent ovarian or peritoneal carcinoma.
Project Period:	7/19/2002 – current
Project Amount:	283,000.00
Agency:	OrthoBiotech
Title:	A phase II trial of Doxil and carboplatin in advanced and recurrent endometrial carcinoma
Project Period:	8/7/2003 – current
Project Amount:	\$104,000.00
Agency:	OrthoBiotech
Title:	A phase II trial of Doxil, carboplatand paclitaxel in with G-CSF in advanced and recurrent endometrial carcinoma
Project Period:	8/7/2003 – current
Project Amount:	\$130,000.00

Peter G. Rose, M.D.

Page 14

SCIENTIFIC JOURNALS

Ad Hoc Reviewer:

Obstetrics & Gynecology
American Journal of Obstetrics and Gynecology
Cancer
Gynecologic Oncology
New England Journal of Medicine
Journal of Reproductive Medicine
Cancer Detection and Prevention
Journal of Clinical Oncology
Journal of the American Medical Association
Southern Medical Journal
Cancer Investigation
Oncology
Archives of Medical Research

Editorial Board:

Gynecologic Oncology: Associate, 2001-present
Current Treatment Options in Oncology: Guest Ed 2003
Cancer: Editorial Advisory Board 2003-present

PUBLICATIONS
ORIGINAL ARTICLES

1. Rose PG, Johnston GC, O'Toole RV. Pure cutaneous histiocytosis X of the vulva. *Obstet Gynecol* 64:587-590, 1984.
2. Rose PG, Strohm PL, Zuspan FP. Fetomaternal hemorrhage following trauma. *Am J Obstet Gynecol* 153:844-847, 1985.
3. Rose PG, Essig GF, Vaccaro PS, Brandt JT. Protein S deficiency in pregnancy. *Am J Obstet Gynecol* 155:140-141, 1986.
4. Rose PG, Bouselis JG, Sachs L. Adjuvant therapy for stage I uterine sarcoma. *Am J Obstet Gynecol* 156:660-662, 1987.
5. Rose PG, Koolemans-Beynen A, Bouselis JG, Minton JP, Milo GE. An improved human tumor stem cell assay in ovarian cancer. *Am J Obstet Gynecol* 156:730-734, 1987.
6. Rose PG, O'Toole RV, Keyhani-Rafagha S, Qualman S, Bouselis JG. Malignant peripheral primitive neuroectodermal tumor of the uterus. *J Surg Oncol* 35:165-169, 1987.
7. Rose PG, Herterick EE, Bouselis JG, Moeshberger M, Sachs L. Multiple primary gynecologic neoplasms. *Am J Obstet Gynecol* 157:261-267, 1987.
8. Piver MS, Rose PG. Long-term follow-up and complications of infants with vulvovaginal embryonal rhabdomyosarcoma treated with surgery, radiation therapy and chemotherapy. *Obstet Gynecol* 71:435-437, 1988.
9. Piver MS, Rose PG. Advanced uterine sarcoma: Response to chemotherapy. *Eur J Gynecol Oncol* 9:124-129, 1988.
10. Rose PG, Piver MS, Tsukada Y, Lau T. Conservative therapy for melanoma of the vulva. *Am J Obstet Gynecol* 159:52-55, 1988.
11. Rose PG, Piver MS, Batista E. Patient-controlled analgesia for gynecologic oncology patients. *J Reprod Med* 34:651-654, 1989.
12. Rose PG, Piver MS. Alternating methotrexate and dactinomycin in non-metastatic gestational trophoblastic disease. *J Surg Oncol* 41:148-152, 1989.
13. Rose PG, Piver MS, Tsukada Y, Lau T. Patterns of metastasis in uterine sarcoma: An autopsy study. *Cancer* 63:935-938, 1989.
14. Rose PG, Piver MS, Tsukada Y, Lau T. Patterns of metastasis in histologic variants of ovarian cancer: An autopsy study. *Cancer* 64:1508-1513, 1989.
15. Rose PG, Piver MS, Tsukada Y. Fallopian tube cancer – The Roswell Park experience. *Cancer* 66:2661-2667, 1990.

PUBLICATIONS

ORIGINAL ARTICLES (Con't)

16. Rose PG, Roman LD, Reale FR, Tak WK, Hunter RE. Primary adenocarcinoma of the breast arising in the vulva. *Obstet Gynecol* 76:537-539, 1990.
17. Rose PG, Reale FR, Longcope C, Hunter RE. Prognostic significance of estrogen and progesterone receptors in epithelial ovarian cancer. *Obstet Gynecol* 76:258-263, 1990.
18. Rose PG, Cohen SM. Methotrexate therapy for persistent ectopic pregnancy after conservative laparoscopic management. *Obstet Gynecol* 76:947-949, 1990.
19. Rose PG, Piver MS. Primary resection of vaginal metastasis with the CUSA in stage III endometrial carcinoma. *Gynecol Oncol* 39:264-265, 1990.
20. Hnatowich DJ, Mardirossian G, Rose PG, Kinders B, Ruschowski M, Hunter RE, Griffin T, Brill A. Intraperitoneal therapy of ovarian cancer with yttrium-90 labeled monoclonal antibodies – Preliminary observations. *Antibody, Immunoconjugates and Radiopharmaceutical* 4:359-371, 1991.
21. Pastner B, Rose PG. CUSA splenorrhaphy for ovarian cytoreductive surgery. *Gynecol Oncol* 41:28-29, 1991.
22. Rose PG, Reale FR, Fischer A, Hunter RE. Appendectomy in primary and secondary staging operations for ovarian malignancy. *Obstet Gynecol* 77:116-118, 1991.
23. Hunter RE, Griffin TW, Stevens S, Roman LD, Bokhari F, Reale FR, Tak WK, Fitzgerald TJ, Dillon MB, Rose PR. High dose/short duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer: *Cancer* 68:1890-1894, 1991.
24. Young SB, Rose PG, Reuter KL. Preoperative assessment vaginal fibroma: Resection and reconstruction of two cases. *Obstet Gynecol* 78:972-974, 1991.
25. Rose PG, Reale FR. Papillary serous carcinoma of the peritoneum following endometrial cancer. *Obstet Gynecol* 78:980-983, 1991.
26. Rose PG, Tak WK, Reale FR, Hunter RE. Adenoid cystic carcinoma of the vulva: A radiosensitive tumor: *Gynecol Oncol* 43:81-83, 1991.
27. Rose PG. The cavitation ultrasonic surgical aspirator (CUSA) for cytoreduction in advanced ovarian cancer: *Am J Obstet Gynecol* 166:843-846, 1992.
28. Rose PG, Halter SA, Su CM. The effect of indomethacin on acute radiation induced gastrointestinal injury. *J Surg Oncol* 49:231-238, 1992.
29. Shim JK, Rose PG, Reale FR, Soto H, Tak WK, Hunter RE. Accuracy of frozen section diagnosis at surgery in clinical stage I and II endometrial carcinoma: *Am J Obstet Gynecol* 66:1335-1338, 1992.
30. Bur M, Perlman C, Edelmann L, Fey E, Rose PG. P53 expression in tumors of the uterine corpus: *Am J Clin Path* 98:81-87, 1992.

PUBLICATIONS
ORIGINAL ARTICLES (Con't)

31. Rose PG, Nelson BE, Fournier L, Hunter RE. Serum squamous cell carcinoma antigen levels in invasive squamous vulvar cancer: A final report. *J Surg Oncol* 50:183-186, 1992.
32. Rose PG, Cha SD, Tak WK, Fitzgerald T, Reale F, Hunter RE. Radiation therapy for surgically proven paraaortic node metastasis in endometrial carcinoma: *Int J Radiat Oncol Biol Phys* 24:229-233, 1992.
33. Rose PG, Nelson BE, Reale FR. False positive elevation of CA-125 in papillary serous carcinoma of the endometrium treated with postoperative whole abdominal radiation. *Gynecol Oncol* 47:127-129, 1992.
34. Rose PG, Baker S, Kern M, Fitzgerald TJ, Tak WK, Reale FR, Nelson BE, Hunter RE. Primary radiation therapy for endometrial carcinoma: A case controlled study. *Int J. Radiat Oncol Biol Phys* 27:585-590, 1993.
35. Rose PG, Piver MS, Malfetano JH, Baker TR, Hempling RE, Recio FO. Phase II study of weekly cisplatin followed by cisplatin and ifosfamide in advanced or recurrent carcinoma of the cervix. *Cancer* 71:2245-2249, 1993.
36. Rose PG, Baker S, Fournier L, Nelson BE, Hunter RE. Serum squamous cell carcinoma antigen levels in invasive cervical cancer: Prediction of response and recurrence. *Am J Obstet Gynecol* 168:942-946, 1993.
37. Rose PG, Cheeseman SH. Advanced ovarian carcinoma managed in an HIV positive patient. *Gynecol Oncol* 48:132-134, 1993.
38. Rose PG, Reale FR, Beurskens ML, Hunter RE. Preoperative CA-125 levels predict the pathologic extent of disease in FIGO grade 1 and 2, clinical stage I and II endometrial adenocarcinoma. *Int J Gynecol Cancer* 3:259-263, 1993.
39. Nelson BE, Rose PG. Malignant pericardial effusion from squamous cell cancer of the cervix. *J Surg Oncol* 52:203-206, 1993.
40. Rose PG, Fraire AE. Multiple primary gynecologic neoplasms in a young HIV positive patient. *J Surg Oncol* 53:203-206, 1993.
41. Nelson BE, Rose PG, Reale FR. Isolated parenchymal splenic metastasis in epithelial ovarian cancer. *Gynecol Oncol* 50:124-127, 1993.
42. Rose PG, Tak WK, Reale FR. Squamous cell carcinoma arising in a mature cystic teratoma with metastasis to the paraaortic nodes. *Gynecol Oncol* 50:131-133, 1993.
43. Rose PG, Reale FR. Serous papillary carcinoma of the cervix. *Gynecol Oncol* 50:361-364, 1993.

PUBLICATIONS

ORIGINAL ARTICLES (Con't)

44. Bjornsson BL, Nelson BE, Reale FR, Rose PG. Accuracy of frozen section for lymph node metastasis in patients undergoing radical hysterectomy for carcinoma of the cervix. *Gynecol Oncol* 51:50-53, 1993.
45. Rose PG, MacFee MS, Boswell MV. Fentanyl transdermal system overdose secondary to cutaneous hyperthermia. *Anesth Analg* 77:390-391, 1993.
46. Rose PG, Hunter RE. Advanced ovarian cancer discovered in a patient with a family history of familial ovarian cancer at referral for prophylactic oophorectomy: *J Reprod Med* 39:908-910, 1994.
47. Rose PG, Terrien JM, Baker S. D-Dimer and peritoneal CA-125 levels as predictors of disease status in ovarian carcinoma. *J Surg Oncol* 56:168-171, 1994.
48. Rose PG, Wilson G. Advanced cervical carcinoma presenting with toxic shock syndrome. *Gynecol Oncol* 52:264-266, 1994.
49. Rose PG, Rubin RB, Nelson BE, Hunter RE, Reale FR. Accuracy of frozen section (intraoperative consultation) diagnosis of ovarian tumors. *Am J Obstet Gynecol* 171:823-826, 1994.
50. Rose PG, Sommers RM, Reale FR, Hunter RE, Fournier L, Nelson BE. Serial serum CA-125 measurement for evaluation of recurrence in patients with endometrial carcinoma. *Obstet Gynecol* 84:12-16, 1994.
51. Rose PG, Piver MS. Intestinal perforation secondary to paclitaxel in ovarian cancer. *Gynecol Oncol* 57:270-272, 1995.
52. Neary BA, Rose PG. Complete response of a persistent ectopic pregnancy to dactinomycin after methotrexate failure. *J Reprod Med* 40:160-162, 1995.
53. Rose PG, Reuter K, Sirois J, Fournier L, Reale FR, Nelson BE, Hunter RE. The impact of CA-125 on the sensitivity of abdominal/pelvic CT scan before second look laparotomy in ovarian cancer: *Int J Gynecol Cancer* 6:213-218, 1996.
54. Rose PG. Hyperglycemia secondary to megestrol acetate for endometrial neoplasia. *Gynecol Oncol* 61:139-141, 1996.
55. Rose PG, Blessing JS, Lewandowski GS, Creasman WT, Webster KD. A phase II trial of prolonged oral etoposide as second line therapy for advanced and recurrent endometrial carcinoma: A Gynecologic Oncology Group study. *Gynecol Oncol* 63:101-104, 1996.
56. Rose PG, Blessing JS, Arseneau JC. A phase II trial of hexamethylmelamine as second line therapy for advanced or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. *Gynecol Oncol* 62:100-102, 1996.

PUBLICATIONS

ORIGINAL ARTICLES (Con't)

57. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Rouillet B, Homesley H, Belpomme D, Glick J. Amifostine pretreatment for protection against cyclophosphamide – and cisplatin – induced toxicities in patients with advanced ovarian cancer. *J Clin Oncol* 14:2101-2112, 1996.
58. Rose PG. Operative retroperitoneal ureteral catheterization for obstructive uropathy in primary locally advanced carcinoma of the cervix: Description of a technique and experience. *Gynecol Oncol* 61:79-82, 1996.
59. Rose PG. Cerebrovascular embolization of choriocarcinoma. *Obstet Gynecol* 88:738, 1996.
60. Broun ER, Iseminger KA, Rose PG, Lentz SL, Malfetano JH, Lincoln S, Mannel R. A phase II trial of edatrexate in previously treated squamous cell cervical cancer: A Gynecologic Oncology Group study. *Am J Clin Oncol* 20:78-80, 1997.
61. Rose PG, Abdul-Karim FW. Isolated appendiceal metastasis in early ovarian carcinoma. *J Surg Oncol* 64:246-247, 1997.
62. Rose PG, Rodriguez M, Abdul-Karim FW. Malignant mixed mullerian tumor of the female peritoneum: Treatment and outcome of three cases. *Gynecol Oncol* 65:523-525, 1997.
63. Markman M, Rose PG, Jones E, Horowitz IR, Kennedy A, Webster K, Belinson J, Fusco N, Fluellen L, Kulp B, Peterson G, McGuire WP. Ninety-six hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens. *J Clin Oncol* 16:1849-1851, 1998.
64. Varia MA, Bundy B, Depe G, Mannell R, Averette H, Rose P, Connely P. Cervical carcinoma metastatic to the paraaortic nodes: Extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy therapy: A Gynecologic Oncology Group study. *Int J Radiat Oncol Biol Phys* 42:1015-1023, 1998.
65. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinoma: A Gynecologic Oncology Group study. *J Clin Oncol* 16:45-410, 1998.
66. Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and platinum for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. *J Clin Oncol* 16:1494-1497, 1998.
67. Cheng L, Wolf NG, Rose PG, Rodriguez M, Abdul-Karim FW. Peritoneal washing cytology of ovarian tumors of low malignant potential. *Acta Cytologica* 42:1091-1094, 1998.
68. Rose PG, Blessing JA, Soper J, Barter JF. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: A Gynecologic Oncology Group (GOG) study. *Gynecol Oncol* 70:267-271, 1998.

PUBLICATIONS

ORIGINAL ARTICLES (Con't)

69. Rose PG, Blessing JA, Van Lee L, Waggoner S. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group (GOG) study. *Gynecol Oncol* 70:263-266, 1998.
70. Rose PG, Fusco N, Fluellen L, Rodriguez M. Carboplatin hypersensitivity reactions in patients with ovarian and peritoneal carcinoma. *Int J Gynecol Cancer* 8:365-368, 1998.
71. Rose PG, Mendelsohn G, Kornbluth I. Hysteroscopic dissemination of endometrial carcinoma. *Gynecol Oncol* 71:145-146, 1998.
72. Rose PG, Arafah B, Abdul-Karim FW. Malignant struma ovarii: Recurrence and response to treatment monitored by thyroglobulin levels. *Gynecol Oncol* 70:425-427, 1998.
73. Rose PG, Abdul-Karim FW. Inadequacy of laparoscopic excision of a malignant ovarian tumor. *J Gynecol Tech* 4:35-36, 1998.
74. Rose PG, Stoler MH, Abdul-Karim FW. Papillary squamotransitional cell carcinoma of the vagina: A case report. *Int J Gynecol Pathol* 17:372-375, 1998.
75. Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW, Miraldi F. Positron emission tomography (PET) for evaluating paraaortic nodal metastasis in locally advanced cervical cancer prior to surgical staging: A surgico-pathologic study. *J Clin Oncol* 17:41-45, 1999.
76. Rose PG, Basile V. Palliative sclerosis of intra-abdominal cystic ovarian or peritoneal carcinoma. *Gynecol Oncol* 72:256-260, 1999.
77. Rose P, Bundy B, Thigpen T, Deppe G, Maiman M, Clarke-Pearson D, Watkins E, Insalaco S. Concurrent cisplatin-based chemotherapy and radiotherapy for locally advanced cervical cancer. *New Engl J Med* 340:1144-1153, 1999.
78. Baciewicz AM, Heugel AM, Rose PG. Nafcillin-warfarin drug interaction. *J Pharm Tech* 15:5-7, 1999.
79. Rader A, Rose PG, Rodriguez M, Mansbacher S, Pitlik D, Abdul-Karim FW. Atypical squamous cells of undetermined significance (ASCUS) in women greater than 55 years of age: Comparison with the general population and implications for management. *Acta Cytol* 43:357-362, 1999.
80. Rose PG, Tak WK, Fitzgerald TJ, Reale FR, Hunter RE, Nelson BE. Brachytherapy for early endometrial carcinoma: A comparative study with long-term follow-up. *Int J Gynecol Cancer* 9:105-109, 1999.
81. Rose PG, Blessing JA, Gershenson DM, McGhee R. Paclitaxel and cisplatin as first line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. *J Clin Oncol* 17:2676-2680, 1999.

PUBLICATIONS

ORIGINAL ARTICLES (Con't)

82. Rose PG, Brandewie EV, Abdul-Karim FW. Failure of megestrol acetate to reverse Tamoxifen induced endometrial neoplasia: Two case reports. *Int J Gynecol Cancer* 9:362-364, 1999.
83. Markman M, Blessing JA, DeGeest K, Morgan M, Look KY, Herzog T, Rose PG. Lack of efficacy of 24-hour infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group Trial. *Gynecol Oncol* 75:444-446, 1999.
84. Rose, PG, Fusco N, Fluellen L, Rodriguez M. Tolerance of twenty-four hour paclitaxel and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube carcinoma. *Int J Gynecol Cancer* 9:448-451, 1999.
85. Rose PG, Skin bridge recurrences in vulvar cancer: Frequency and management. *Int J Gynecol Cancer* 9:508-511, 1999.
86. Nakamura H, Rose PG, Blumer JL, Reed MD. Acute encephalopathy due to aluminum toxicity successfully treated by combined intravenous deferoxamine and hemodialysis. *J Clin Pharm* 40:296-300, 2000.
87. Rose PG, Shrigley R, Wiesner GL. Germline BRCA2 mutation in a patient with fallopian tube carcinoma: A case report. *Gynecol Oncol* 77:319-320, 2000.
88. Rose PG, Lappas PT. Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: Implications from five randomized trials *Gynecol Oncol* 78:3-6, 2000.
89. Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A phase II study of anastrozole in recurrent or persistent endometrial carcinoma. *Gynecol Oncol* 78:212-216, 2000.
90. Rose PG, Gordon N, Fusco N, Fluellen L, Rodriguez M, Ingalls S, Hoppel CL. A phase II and pharmacokinetic study of weekly 72 hour topotecan infusion in patients with platinum resistant and paclitaxel resistant ovarian carcinoma. *Gynecol Oncol* 78:228-234, 2000.
91. Rose PG, Alvarez B, MacLennan GT. Exacerbation of endometriosis by Tamoxifen. *Am J Obstet Gynecol* 183:507-508, 2000.
92. Rose PG, Rodriguez M, Waggoner S, Greer BE, Horowitz IR, Fowler JM, McGuire WP. A phase I study of paclitaxel, carboplatin and increasing doses of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: A Gynecologic Oncology Group study. *J Clin Oncol* 18:2957-2962, 2000.
93. Gordon AN, Granai CO, Rose P, Hainsworth J, Lopez A, Weissman C, Rosales R, Sharpington T. Phase II study of stealth liposomal doxorubicin (Doxil) in platinum and paclitaxel refractory epithelial ovarian cancer. *J Clin Oncol* 18:3093-3100, 2000.
94. O'Leary AW, Rose PG, Rodriguez M, Shina DC, Pham H, Kinsella TJ. Ultrasound assisted intrauterine tandem placement in advanced cervical cancer. *J Brachytherapy Int* 16:169-172, 2000.

PUBLICATIONS

ORIGINAL ARTICLES (Con't)

95. Curtin JP, Blessing JA, Webster KD, Rose PG, Mayer A, Fowler WC, Malfetano JF, Alvarez RD. Paclitaxel – an active agent in adenocarcinoma of the uterine cervix, a Gynecologic Oncology Group study. *J Clin Oncol* 19:1275-1278, 2001.
96. Sarode V, Rader A, Rose PG, Rodriguez M, Abdul-Karim FW. Significance of cytologically normal endometrial cells in cervical smears from postmenopausal women. *Acta Cytol* 45:153-156, 2001.
97. Francasso PM, Brady MF, Moore DH, Walker JL, Rose PG, Letvak L, Grogan TM, McGuire WP. Phase II study of paclitaxel and PSC 833 (valspodar) in refractory ovarian carcinoma: A gynecologic Oncology Group study. *J Clin Oncol* 19:2975-2982, 2001.
98. Rose P, Faulhaber P, Miraldi F, Abdul-Karim F. Positive Emission Tomography for Evaluating a Complete Clinical Response in Patients with Ovarian Carcinoma Correlated with Second Look Laparotomy. *Gynecol Oncol* 82:17-21. 2001.
99. Rose PG, Hawthorne-Maxson J, Fusco N, Mossbrugger K, Rodriguez M. Liposomal doxorubicin in ovarian, peritoneal and tubal carcinoma: A retrospective comparative study of single agent dosages. *Gynecol Oncol* 82:323-328, 2001.
100. Rodriguez M, Guimares O, Rose PG. Radical abdominal trachelectomy and pelvic lymphadenectomy with uterine conservation and subsequent pregnancy in the treatment of invasive cervical cancer: Two case reports. *Am J Obstet Gynecol* 185:370-374, 2001.
101. Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan in platinum and paclitaxel resistant ovarian cancer. *Gynecol Oncol* 83:257-262, 2001.
102. Rose PG, Rodriguez M, Greer BE, Walker J, Fusco N, McGuire WP. A Phase I study of oral etoposide and liposomal doxorubicin in ovarian, peritoneal and tubal carcinoma: A Gynecologic Oncology Group Study. *Gynecol Oncol* 85:136-139, 2002.
103. Wang N, Emancipator SN, Rose P, Rodriguez M, Abdul-Karim FW. Histologic follow-up of atypical endocervical cells: ThinPrep Pap test vs. conventional Pap smear. *ACTA Cytol* 46:453-457, 2002.
104. Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW, Charpentier D. A Phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. *Gynecol Oncol* 86:302-310, 2002.
105. Green AE, McCrae K, Rose PG. Arterial thrombosis in gynecologic oncology patient: Evaluation and management. *Gynecol Oncol* 87:228-230, 2002.
106. Rose PG, Mossbrugger K, Fusco N, Smrekar M, Eaton S, Rodriguez M. Gemcitabine reverses cisplatin resistance: Demonstration of activity in platinum and multi-drug resistant ovarian and peritoneal carcinoma. *Gynecol Oncol* 88:17-21, 2003.

PUBLICATIONS

ORIGINAL ARTICLES (Con't)

107. Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, Moore DH. A phase II study of docetaxel in paclitaxel resistant ovarian and peritoneal carcinoma: A Gynecologic Oncology Group Study. *Gynecol Oncol* 88,130-135, 2003.
108. Rose PG, Fusco N, Smrekar M, Mossbrugger K, Rodriguez M. Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. *Gynecol Oncol* 89, 429-433, 2003
109. Rose PG, Blessing JA, Buller RE, Mannel RS, Webster KD. Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. *Gynecol Oncol* 89;267-270, 2003
110. Rose PG, Smrekar M. Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel. *Gynecol Oncol* 91,423-425, 2003.
111. Escobar PF, Markman M, Rose PG, Zanotti K, Webster K, Belinson J. Phase II Trial of carboplatin, paclitaxel and irinotecan in ovarian, fallopian tube and primary peritoneal cancers. *Gynecol Oncol* (Accepted).
112. Green AE, Abdul-Karim F, Al-Ali R, Rose PG. Primary Retroperitoneal Cystadenocarcinoma: Confirmation of histologic origin. (Submitted *Int J Gynecol Pathol*)
113. Fracasso PM, Blessing JA, Molpus K, Adler LM, Sorosky JI, Rose PG. Phase II study of oxaliplatin in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. (Submitted *Gynecol Oncol*)
114. Look KY, Sandler A, Blessing JA, Lucci J, Rose PG. Phase II trial of gemcitabine in persistent or recurrent leiomyosarcoma: A Gynecologic Oncology Group study. (Submitted *Gynecol Oncol*)
115. Schilder RJ, Blessing JA, Pearl ML, Rose PG. Evaluation of iriflufen (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. (Submitted *Invest New Drugs*)
116. Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, Moore DH. Phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. (Submitted *GOG Publications Committee*).
117. Rose PG, Markman M, Bell JG, Fusco NL, McGuire WP. A Phase I Study Of Sequential Prolonged Oral Topotecan And Prolonged Oral Etoposide As Second Line Therapy In Ovarian, Peritoneal Or Tubal Carcinoma. (Submitted *GOG Publications*).
118. Rose PG, Smrekar M, Fusco NL. A phase II trial of weekly paclitaxel and every three week carboplatin in potentially platinum sensitive ovarian and peritoneal carcinoma. (Submitted *Gynecol Oncol*).

119. Connelly RW, Rose PG. Insulin like growth factor-1 (IGF-1) upregulation of heat shock protein 27KDA(HSP27): A potential mechanism of cisplatin resistance in a human ovarian cancer cell line. (Submitted Gynecol Oncol).
120. Dubay RA, Rose PG, O'Malley DM, Shalodi AD, Ludin A, Selim MA. Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. (Submitted Gynecol Oncol).
121. Winter WE, Maxwell GL, Tian C, Elkas JC, Rose GS, Ozols RF, Rose PG, Spriggs D, Armstrong D, Muggia F, McGuire W, Carlson JW. Prognostic factors for advanced epithelial cancer: a Gynecologic Oncology Group study. (Submitted GOG Publications Committee).

121. CHAPTERS AND REVIEWS

1. Piver MS, Rose PG. Chemotherapy of epithelial ovarian cancer. In: Deppe G (ed.), Chemotherapy of Gynecologic Cancer, Second Ed. Alan Liss, Inc. New York (1990).
2. Rose PG. Uterine sarcoma. In: Piver MS (ed.), Manual of Gynecologic Oncology. Little Brown and Company, Inc. Boston 1989.
3. Bunin GR, Rose PG, Noller KL, Smith E. Carcinogenesis. In: Paul M. (ed.) Occupational and Environmental Reproductive Hazards: A Guide for Clinicians. Williams and Wilkins, Inc. Baltimore 1993.
4. Rose PG. Endometrial carcinoma. ACOG Interactive Computer Disc. ACOG 1993.
5. Rose PG. Screening and the detection of early cervical cancer. *Emergency Medicine* 25:133-140, 1993.
6. Rose PG. Locally advanced cervical carcinoma.: The role of chemoradiation. *Sem Oncol* 21:47-53, 1994.
7. Rose PG. Hydatiform mole: Diagnosis and management. *Sem Oncol* 22:149-156, 1995.
8. Rose PG. Uterine sarcoma. In: Piver MS (ed.), Handbook of Gynecologic Oncology. Little Brown and Company, Inc. Boston, 1996.
9. Rose PG. Fallopian tube cancer. In: Piver MS (ed.), Handbook of Gynecologic Oncology. Little Brown and Company, Inc. Boston, 1996.
10. Rose PG. Cases No 5, 24, and 47. In Belinson JL and Markman M (eds) Expert Consultations in Gynecologic Malignancies. Marcel Dekker, Inc. New York, 1996.
11. Rose PG. Amifostine for advanced ovarian carcinoma. *Sem Oncol* 23:83-89, 1996.
12. Rose PG. Endometrial adenocarcinoma. *New Engl J Med* 335:640-649, 1996.
13. Rose PG. Gastrointestinal surgery in gynecologic oncology. *Seminars in Colon and Rectal Surgery* 8:206-214, 1997.
14. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second line therapy for platinum resistant and platinum sensitive ovarian carcinoma: A Gynecologic Oncology Group study. *Classic Papers and Current Comments*, 3: 230-23, 1998.
15. Rose PG. Chemotherapy of cervical cancer. In: Deppe G, Baker V. (eds), Gynecologic Cancer: Principles and practice of chemotherapy. Chapman & Hall, New York 1999.

CHAPTERS AND REVIEWS (Con't)

16. Rose PG. Fallopian tube cancer. In: Textbook of Uncommon Cancer, Second Ed. Raghavan D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Thigpen JT (eds), John Wiley & Sons, Ltd., Sussex England 1999, pp 689-700.
17. Rose PG. Uterine Sarcoma. In: Textbook of Uncommon Cancer, Second Ed. Raghavan D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Thigpen JT (eds), John Wiley & Sons, Ltd., Sussex, England 1999, pp 689-700.
18. Rose PG. Concurrent chemotherapy and radiation therapy for cervical cancer. ASCO Fall Education Book 1999, Alexandria, VA.
19. Rose PG. Chemo-irradiation of cervical carcinoma: Where do we stand now? Vlaamse Vereniging Voor Obstetrie En Gynaecologie, Jaarboek 1999.
20. Rose PG, Eifel PJ. Combined modality treatment for carcinoma of the cervix. In: Devita VT, Hellman S, Rosenberg SA, (eds). Principles and Practice of Oncology Updates. Volume 14, Number 6. 2000.
21. Rose PG. Chemoradiotherapy: The new standard of care for invasive cervical cancer. *Drugs* 60:1239-1244, 2000.
22. Rose PG. Surgery for recurrent ovarian cancer. *Sem Oncol* 27 (7):17-23, 2000.
23. Rose PG, Eifel PJ. Chemotherapy and radiation therapy for cervical cancer. ASCO Spring Education Book 2000, Alexandria, VA.
24. Rose PG. Advances in the Management of Cervical Cancer. *J Reprod Med.* 45 (12): 971-978, 2000.
25. Rose PG. ASCO 2000: Update on Ovarian Cancer. *Federal Forum Supplement*. September 2000.
26. Rose PG. Editorial: Type II Radical Hysterectomy: Evaluating it's Role in Cervical Cancer. *Gynecol Oncol* 80:1-2, 2001.
27. Rose PG. Locally advanced cervical cancer. *Current Opinion in Obstet Gynecol* 13:65-70, 2001.
28. Rose PG, Eifel PJ. Combined radiation therapy and chemotherapy for carcinoma of the cervix. *Cancer J* 7:86-94, 2001.
29. Rose PG, Lappas PT. Pharmacoeconomics of Cisplatin-based Chemoradiation in Cervical Cancer. *Oncology Spectrums* 2:32-36:2001.
30. Rose PG, Bundy BN. Editorial: Chemoradiation for locally advanced cervical cancer: Does it help? *J Clin Oncol* 20:891-893, 2002.
31. Rose PG. Chemo-Radiotherapy for cervical cancer. *Eur J Cancer* 38:270-278, 2002.

CHAPTERS AND REVIEWS (Con't)

32. Rose PG. Carcinoma of the Endometrium in Conn's Current Therapy 2003 edition.(In press)
33. Rose PG, Lappas PT. Pharmacoeconomics of cisplatin-based chemoradiation in cervical cancer: a review. *Expert Opin Pharmacother* 3:1245-1249, 2002.
34. Cannistra SA, Bast RC, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP, Rose PG, Rowinsky EK, Ruston GJS, Skates SJ, Vasey PA, King L. Progress in the Management of Gynecologic Cancer: Consensus Summary Statement. *J Clin Oncol* 21;129s-132s, 2003.
35. Rose PG. Combined Modality Therapy of Locally Advanced Cervical Cancer. *J Clin Oncol* 21;211s-217s, 2003.
36. O'Malley D, Rose PG. New Recommendations for the treatment of bulky stage I and advanced stage cervical cancer with chemoradiation. *Postgraduate Obstetrics and Gynecology* . *Postgraduate Obstetrics & Gynecology* 23(9):1-8, 2003.
37. Rose PG. Chemotherapy for Newly Diagnosed and Relapsed Advanced Ovarian Cancer. *Seminars in Oncology Nursing* 19(4):25-35, 2003.
38. Koh WJ, Rose PG. Locally Advanced Cervical Cancer. In Gershenson, Gore, McGuire, Quinn, Thomas G (eds), *Gynecologic Oncology: Controversies in Management*. Elsevier Science (In Press).
39. Rose PG. Stage IIB-IVA of Cervix Cancer. In Berek J. (ed), *The Cancer Journal* (In Press).
40. Lee KR, Rose PG, Crum CP. The Cervix. In Crum CP (ed) : *Gynecologic Pathology* W.B. Saunders Publishers, Philadelphia, PA (In Press)
41. Rose PG: Surgical Staging in Locally Advanced Cervical Cancer. *Oncology*. (In Press)
42. Stehman FB, Rose PG, Greer BE, Roy M, Plante M, Penalver M, Jhingran A, Eifel P, Montz F, Wharton JT. Innovations in the Treatment of Invasive Cervical Cancer. *Cancer*;98(9 Suppl):2052-63, 2003.
43. Rose PG. Chemotherapy for Newly Diagnosed and Relapsed Advanced Ovarian Cancer. *Sem Oncol Nurs* 19;25-35:2003.

PUBLISHED ABSTRACTS

1. O'Toole RV, Rofagha-Keyhani S, Qualman S, Rose P, Boutselis J, Feinberg M. Primitive neuroectodermal tumor of the uterus: A case report with Papanicolaou smear findings. Presented at the 33rd Annual Meeting of the American Cytological Society. *Acta Cytologica* 29:945, 1985.
2. Rose PG, Piver MS, Tsukada Y, Lau T. Patterns of metastasis in uterine sarcoma. An autopsy study. *Gynecol Oncol* 32:96, 1989.
3. Hnatowich DJ, Stevens S, Kinders RJ, Rusckowski M, Rose P, Hunter R, Griffin T, Brill AB. Intraperitoneal yttrium-90 immunotherapy in ovarian cancer patients. *Journal of Nuclear Medicine* 30:828, 1989.
4. Hunter RE, Griffin T, Stevens S, Rose PG, Bokhari F. High-dose/short-duration doxorubicin/cis-platinum combination chemotherapy for advanced ovarian epithelial cancer. *Gynecol Oncol*, 36:288, 1990.
5. Rose PG, Piver MS, Tsukada Y. Primary fallopian tube cancer – The Roswell Park experience. *Gynecol Oncol*, 36:294, 1990.
6. Rose PG, Reale FR, Longcope C, Hunter RE. Prognostic significance of estrogen and progesterone receptors in epithelial ovarian cancer. *Gynecol Oncol*, 36:294, 1990.
7. Rose PG, Reale FR, Fischer A, Hunter RE. Appendectomy in primary and secondary staging operations for ovarian malignancy. *Gynecol Oncol*, 40:185, 1991.
8. Rose PG, Reale FR, Beurskens ML, Hunter RE. Preoperative CA-125 levels predict the pathologic extent of disease in FIGO grade 1 and 2, clinical stage I and II endometrial adenocarcinoma. *Gynecol Oncol* 45:105, 1992.
9. Schein PS, Kemp GM, Rose PG, Scheffler B and McCulloch W. Results of a randomized trial of cyclophosphamide and cisplatin \pm Ethyol in patients with advanced ovarian cancer. Submitted Seventh International Conference of Chemical Modifiers of Cancer Treatment, 1991.
10. Perlman C, Bur M, Edelmann L, Fey E, Rose P. p53 expression in tumors of the uterus and ovary. *Am J Clin Pathol* 96:408, 1991.
11. Schim JK, Rose PG, Reale FR, Soto H, Tak WK, Hunter RE. Accuracy of frozen section diagnosis at surgery in clinical stage I and II endometrial carcinoma. *Gynecol Oncol* 45:104, 1992
12. Rose PG, Bur M, Savasta A, Reale FR. Her-2/neu expression-A comparison of frozen and paraffin tissue techniques. *Gynecol Oncol* 45:105, 1992.
13. Rose PG, Cha SD, Tak WK, Fitzgerald T, Reale FR, Hunter RE. Radiation therapy for surgically proven paraaortic node metastasis in endometrial carcinoma. Submitted American Radium Society Meeting, 1992.

PUBLISHED ABSTRACTS (Con't)

14. Rose PG, Piver MS, Malfetano JH, Baker TR, Hempling RE, Recio FO. Phase II study of weekly cisplatin followed by cisplatin and ifosfamide in advanced and recurrent carcinoma of the cervix. Proc ASCO 11:234, 1992.
15. Glick J, Kemp G, Rose P, McCulloch, Scheffler B, Schein P. A randomized trial of cyclophosphamide and cisplatin +/- WR 2721 in the treatment of advanced epithelial ovarian cancer. Proc ASCO 11:109, 1992.
16. Kemp G, Rose P, McCulloch W, Schein P. A trial of cisplatin (P) and cyclophosphamide (C) +/- WR 2721 (WR) in advanced ovarian cancer. Gynecol Oncol 45:80, 1992.
17. Bjornsson BL, Nelson BE, Reale FR, Rose PG. Accuracy of frozen section for lymph node metastasis in patients undergoing radical hysterectomy for carcinoma of the cervix. Gynecol Oncol 49:130, 1993.
18. Rose PG, Baker S, Fournier L, Nelson BE, Hunter RE. Serum squamous cell carcinoma antigen levels in invasive cervical cancer: Prediction of response and recurrence. Gynecol Oncol 49:137, 1993.
19. Rose PG, Reuter K, Sirois J, Fournier L, Reale FR, Nelson BE, Hunter RE. The impact of CA-125 on the sensitivity of abdominal/pelvic CT scan before second look laparotomy in ovarian cancer: Gynecol Oncol 49:137, 1993.
20. Rubin R, Rose PG, Nelson BE, Hunter RE, Reale FR. Accuracy of frozen section diagnosis of ovarian tumors. Gynecol Oncol 49:139, 1993.
21. Nelson BE, Reuter K, Rose PG. Preoperative abdominopelvic computerized tomography prediction of optimal cytoreduction in advanced ovarian cancer: Impact of the Cavitron Surgical Aspirator (CUSA). (Gynecol Oncol In Press)
22. Rose PG, Baker S, Kern M, Fitzgerald TJ, Tak WK, Reale FR, Nelson BE, Hunter RE. Primary radiation therapy for endometrial carcinoma: A case controlled study. American Radium Society 1993.
23. Lazzara EW, Davidoff A, Reuter KL, Colby JM, Daley JM, Nelson BE, Rose PG. Metastatic ovarian cancer to the liver imaging manifestations. Assoc of University Radiologists 1994.
24. Glick J, Kemp G, Rose P, Mitchell E, Reynolds R, Scheffler B, Capizzi R. A randomized trial of cyclophosphamide and cisplatin +/- amifostine in the treatment of advanced epithelial ovarian cancer. Proc ASCO 13:432, 1994.
25. Kemp G, Rose P, Glick J, Lurain J, Roulet B, Facchini T, Martin CJ, Belpomme D, Mitchell E, Scheffler B. Selective cytoprotection from the cytotoxicity of cyclophosphamide (C) and cisplatin (P) +/- amifostine (A): A randomized trial in patients with advanced epithelial ovarian cancer. Gynecol Oncol 56:130, 1995.
26. Rose PG, Blessing JS, Lewandowski GS, Creasman WT, Webster KD. A phase II trial of prolonged oral etoposide as second line therapy for advanced and recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Proc ASCO 14:272, 1995.

PUBLISHED ABSTRACTS (Con't)

27. Chase P, Kahn B, Fitzmaurice MA, Ozan D, Rose P. Microwave antigen-retrieval enhances IGF's immunochemistry in the ovary. *Cell Vision* 2:264, 1995.
28. Rose PG, Blessing JS, Arseneau JC. A phase II trial of hexamethylmelamine as second line therapy for advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. *Gynecol Oncol* 60:133, 1996.
29. Rose PG, Chase P, Abdul-Karim FW. Insulin-like growth factor (IGF) – I, IGF – II and IGF – receptor expression in epithelial ovarian cancer. *Gynecol Oncol* 60:125, 1996.
30. Markman M, Rose P, Kennedy A, Fusco N, Webster K, Fluellen L, Belinson J. A phase II Study of 96 hour paclitaxel (P) as salvage therapy in ovarian carcinoma. *Proc ASCO* 15:283, 1996.
31. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second line therapy for platinum resistant (PlatR) and platinum sensitive (PlatS) ovarian carcinoma: A Gynecologic Oncology Group study. *Proc ASCO* 15:282, 1996.
32. Rose P, Kemp G, Glick J. Ethylol (amifostine) protects against cumulative cisplatin toxicities. *Proc ASCO* 15:533, 1996.
33. Varia MA, Bundy B, Deppe G, Mannell R, Averette H, Rose P, Connelly P. Cervical carcinoma metastatic to the para-aortic nodes: Extended field radiation therapy with concomitant 5-FU/cisplatin chemotherapy. A Gynecologic Oncology Group study. *Int J Radiat Oncol Biol Phys* 36:220;1996.
34. Rose PG, Ethylol (amifostine) protects against cumulative cisplatin toxicities. *Cancer Invest* 15:9, 1996.
35. Rose PG, Adler L, Rodriguez M, Miraldi F. Is positive emission tomography (PET) useful in evaluating disease status when computerized tomography (CT) is negative? A surgico-pathologic evaluation in cervical, ovarian and peritoneal carcinoma (CA). *Gynecol Oncol* 64:346, 1997.
36. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second line therapy for platinum resistant (PlatR) and platinum sensitive (PlatS) ovarian carcinoma: A gynecologic Oncology Group study. *Gynecol Oncol* 64:309, 1997.
37. Varia MA, Bundy B, Deppe G, Manell R, Averette H, Rose P, Connelly P. Cervical carcinoma metastatic to the para-aortic nodes: A GOG study of extended field chemoradiation therapy. *Gynecol Oncol* 64:309, 1997.
38. Rose PG, Tak WK, Fitzgerald TJ, Reale FR, Hunter RE, Nelson BE. Brachytherapy for early endometrial carcinoma: A comparative study. *Gynecol Oncol* 64:312, 1997.
39. Rose PG, Blessing JA, Gershenson DM. Paclitaxel and cisplatin as first line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group (GOG) study. *Proc ASCO* 16:363, 1997.

PUBLISHED ABSTRACTS (Con't)

40. Rose P, Bundy B, Thigpen T, Deppe G, Maiman M, Clarke-Pearson D, Watkins E, Insalaco S. Significant preliminary results of a phase III randomized study of concomitant chemoradiation with hydroxyurea vs. hydroxyurea, 5-FU infusion and bolus cisplatin (HFC) vs. weekly cisplatin in advanced cervical cancer. A GOG study. *Gynecol Oncol* 68:104, 1998.
41. Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and platinum for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. *Gynecol Oncol* 68:121, 1998.
42. Rose PG, Blessing JA, Soper J, Barter JF. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: A Gynecologic Oncology Group (GOG) study. *Gynecol Oncol* 68:136, 1998.
43. Rose PG, Fusco N, Fluellen L, Rodriguez M. Carboplatin hypersensitivity reactions following paclitaxel in patients with ovarian and peritoneal carcinoma. *Gynecol Oncol* 68:121, 1998.
44. Rodriguez M, Abdul-Karim F, Nelson B, Sommers R, Ali R, Rose PG. Platinum based chemotherapy is an active compound in advanced and recurrent papillary serous carcinoma of the endometrium. *Gynecol Oncol* 68:135, 1998.
45. Rose PG, Blessing JA, Fowler WC, Waggoner S. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group (GOG) study. *Gynecol Oncol* 68:104, 1998.
46. Rodriguez M, Connelly R, Liu D, Abdul-Karim F, Rose PG. Expression of matrix metalloproteinase 2 protein in normal, benign, and malignant tissues of the ovary. *Gynecol Oncol* 68:88, 1998.
47. Rodriguez M, Connelly R, Liu D, Edinger M, Rose PG. Insulin like growth factor receptor (IGF-IR) expression in two established ovarian cancer cell lines: A potential in vivo model for gene therapy. *Gynecol Oncol* 68:88, 1998.
48. Rose PG, Connelly R, Edinger M, Rodriguez M. Tumor cell autocrine motility factor receptor (AMF-R) expression in ovarian cancer: A potential target for gene therapy. *Gynecol Oncol* 68:89, 1998.
49. Rose PG, Bundy BN, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Watkins E, Insalaco S. Significant preliminary results of a phase III randomized study of concomitant chemoradiation with weekly cisplatin vs hydroxyurea, 5- fluorouracil infusion and bolus cisplatin vs hydroxyurea in advanced cervical cancer, a Gynecologic Oncology Group study. *Proc ASCO* 17:360a, 1998.
50. Gordon AN, Hainsworth J, Moore M, Weissman C, Malfetano J, Wolin E, Kosty M, Peters WA, Granai CO, Lopez AM, Malviya V, Rose P, Rosales R, Teitelbaum AH. Doxil (Doxorubicin HCL liposomal injection) in the treatment of patients with advanced epithelial ovarian carcinoma-results of an interim analysis. *Proc ASCO* 17:349a, 1998.

PUBLISHED ABSTRACTS (Con't)

51. Rose PG, Blessing JA, Gershenson DM, McGhee R. Paclitaxel and cisplatin as first line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group (GOG) study. *Gynecol Oncol* 72:461, 1999.
52. Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW, Miraldi F. Positive emission tomography (PET) for evaluating paraaortic nodal metastasis in locally advanced cervical cancer prior to surgical staging: A surgico-pathologic study. *Gynecol Oncol* 72:458, 1999.
53. Rose PG, Gordan N, Fusco N, Fluellen L, Rodriguez M, Ingalls S, Hoppel CL. A phase II and pharmacokinetic study of weekly 72 hour topotecan infusion in patients with platin resistant and paclitaxel resistant ovarian carcinoma. *Gynecol Oncol* 72:485, 1999.
54. Rose PG, Rodriguez M, Waggoner S, Greer BE, Horowitz IR, Fowler JM, McGuire WP. A phase I study of paclitaxel, carboplatin and increasing doses of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: A Gynecologic Oncology Group study. *Gynecol Oncol* 72:469, 1999.
55. Rose PG, Connelly RW, Abdul-Karim F, Rodriguez M. The role of autocrine motility factor receptor (AMF-R) gene expression in the SK-OV-3 ovarian cancer cell line utilizing antisense technology. *Gynecol Oncol* 72:484, 1999.
56. Rose PG, Connelly RW, Abdul-Karim F, Ferguson K, Rodriguez M. Tumor cell autocrine motility factor receptor (AMF-R) expression in cervical and endometrial cancer cell lines. *Gynecol Oncol* 72:485, 1999.
57. Rodriguez M, Liu D, Connelly RW, Rose PG. Antisense therapy to the type I insulin-like growth factor receptor suppresses cellular proliferation of human ovarian cancer cell lines in vitro. *Gynecol Oncol* 72:478, 1999.
58. O'Leary AW, Rose PG, Rodriguez M, Shina DC, Pham H, Kinsella TJ. Ultrasound assisted intrauterine tandem placement in advanced cervical cancer. (American Radium Society 1999).
59. Samuels M, Mohan DS, Selim MA, Shalodi AD, Rodriguez M, Rose PG. Does pelvic lymphadenectomy have a role in the management of node positive endometrial adenocarcinoma. (American Radium Society 1999).
60. Rose P, Gordon AN, Granai CO, Hainsworth J, Weissman C, Lopez A, Kosty M, Peters WA, Malfetano J, Malviya V, Del Prete SA, Moore M, Wolin E, Goldberg D, Feherenbacher L, Yee SJ, Orr J, Garfied D, Rosales R, Sharpington T. Interim analysis of a non-comparative, multicenter study of Doxil/Caelyx in the treatment of patients with refractory ovarian cancer. *Proc ASCO* 18:360a, 1999.
61. Seiden M, Swenerton K, Matulonis U, Orse P, Batist G, Verma S, Oza A, Popadiuk C, Bessette P, Anger E, Ette E, Harding M, Charpentier D. A phase II study of IncelTM (biricodar, VX-710) + paclitaxel in women with advanced ovarian cancer refractory to paclitaxel (AACR-NCI-EORTC meeting Washington, DC 11/99).

PUBLISHED ABSTRACTS (Con't)

62. Rose PG. Skin bridge recurrences in vulvar cancer: Frequency and management. *Gynecol Oncol* 76:263, 2000.
63. Rodriguez M, Wiseman M, Fusco N, Fluellen L, Rose PG. Lower dose topotecan salvage remains active in platinum and paclitaxel refractory and resistant ovarian cancer. *Gynecol Oncol* 76:261, 2000.
64. Rose PG, Greer BE, Markman M, Horowitz IR, Fusco N, McGuire WP. A phase I study of paclitaxel, carboplatin, and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: A Gynecologic Oncology Group study. *Proc ASCO* 19:387a, 2000.
65. Connelly RW, Chernicky CL, Yi L, Tan H, Rose PG, Rodriguez M, Ilan J. Insulin like growth factor I (IGF-I) protects human ovarian cancer cells from Cisplatin induced cell proliferation in vitro. *Gynecol Oncol* 80:132, 2001.
66. Rose PG, Greer BE, Walker J, Fusco N, McGuire WP. A Phase I study of oral etoposide and liposomal doxorubicin in ovarian, peritoneal and tubal carcinoma: A Gynecologic Oncology Group Study. *Gynecol Oncol* 80:133, 2001.
67. Rose PG, Bundy BN, Watkins E, Thigpen T, Deppe G, Maiman M, Clarke-Pearson D, Insalaco S. Effect of chemoradiation in advanced stage cervical cancer. *Gynecologic Oncology* (In Press)
68. Markman M, Rose PG, Kennedy A, Webster K, Zanotti K, Belinson J. Phase II trial of carboplatin, paclitaxel and irinotecan in ovarian cancer and primary cancer of the peritoneum. (Submitted *Cancer Invest*)
69. Rose PG, Mossbrugger K, Fusco N, Smrekar M, Eaton S, Rodriguez M. Gemcitabine reverses cisplatin resistance: Demonstration of activity in platinum and multi-drug resistant ovarian and peritoneal carcinoma. *Gynecol Oncol* 2002;84:487.
70. Rose PG, Markman M, Bell J. A phase I study of sequential prolonged oral topotecan and prolonged oral etoposide as second line therapy in ovarian, peritoneal or tubal carcinoma. *Gynecol Oncol* 2002;84:509.
71. Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, Moore DH. A phase II study of docetaxel in paclitaxel resistant ovarian and peritoneal carcinoma. A Gynecologic Oncology Group Study. *Gynecol Oncol* 2002;84:508.
72. Connelly RW, Rose PG. Insulin like growth factor-1 (IGF-1) upregulation of heat shock protein 27KDA(HSP27): A potential mechanism of cisplatin resistance in a human ovarian cancer cell line. *Gynecol Oncol* 2002;84:509.
73. Rose PG, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, Rubin SC, Moore DH. Phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: A Gynecologic Oncology Group Study. *Proc ASCO* 21:201a, 2002.

PUBLISHED ABSTRACTS (Con't)

74. Rose PG, Smrekar M, Fusco N. A Phase II trial of weekly paclitaxel and every three week carboplatin in potentially platinum sensitive ovarian and peritoneal carcinoma. Proc ASCO 22:1932, 2003.
75. Dubay R, Rose PG, O'Malley D, Shalodi A, Ludin A, Selim M. Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. Proc ASCO 22, 1978, 2003.
76. Escobar PF, Markman M, Zanotti K, Webster K, Belinson JL, Rose P. Phase II trial of carboplatin, paclitaxel, and ironotecan in ovarian, primary peritoneal, and fallopian tube cancers. Proc ASCO 22:450a, 2003.
77. Rose PG, Smrekar M, Haba P, Visser C. A phase I trial of Weekly topotecan and carboplatin in potentially platinum sensitive ovarian And peritoneal carcinoma. (submitted SGO 2004)
78. Connelly B, Rose PG. Assessment of cisplatin cytotoxicity after p73 gene restoration in a p73 deficient ovarian cancer cell line. (submitted SGO 2004).
79. Winter WE, Maxwell GL, Tian C, Elkas JC, Rose GS, Carlson JW, Ozols RF, Rose PG, Spriggs D, Armstrong D, Muggia F, McGuire W. Prognostic factors for epithelial ovarian cancer (EOC): a Gynecologic Oncology Group (GOG) study. (submitted SGO 2004).
80. Rose PG, Coleman R, Smrekar M. Carboplatin and liposomal doxorubicin for advanced or recurrent endometrial carcinoma. (submitted SGO 2004)

PRESENTATIONS: SCIENTIFIC MEETINGS

1. Fetomaternal Hemorrhage Following Trauma.
Am Coll Obstet/Gyn District 4 meeting: Columbus, OH October 1985.
2. Prognostic Significance of Estrogen and Progesterone Receptors in Epithelial Ovarian Cancer.
New England Assoc Gynecol Oncol, June 1989.
3. Appendectomy for Primary and Secondary Staging Operations in Ovarian Malignancy.
New England Assoc Gynecol Oncol, June 1990.
4. Accuracy of Frozen Section Diagnosis at Surgery in Clinical Stage I and II Endometrial Carcinoma.
New England Assoc Gynecol Oncol, June 1991.
5. The Cavitation Ultrasonic Surgical Aspirator for Cytoreduction in Ovarian Cancer. New England Cancer Society, November 1991.
6. Accuracy of Frozen Section Diagnosis at Surgery in Clinical Stage I and II Endometrial Carcinoma.
New England Cancer Society, November 1991.

PRESENTATIONS: SCIENTIFIC MEETINGS (Con't)

7. Radiation Therapy for Surgically Proven Paraaortic Lymph Node Metastasis in Endometrial Carcinoma.
New England Assoc Gynecol Oncol, June 1992.
8. Advanced Ovarian Carcinoma Managed in an HIV Positive Patient.
New England Assoc Gynecol Oncol, June 1992.
9. The Impact of CA-125 on the Sensitivity of Abdominal/Pelvic CT Before Second Look Laparotomy in Ovarian Carcinoma.
New England Assoc Gynecol Oncol, June 1992.
10. Radiation Therapy for Surgically Proven Paraaortic Lymph Node Metastasis in Endometrial Carcinoma.
New England Cancer Society, November 1992.
11. Accuracy of Frozen Section for Lymph Node Metastasis in Patients Undergoing Radical Hysterectomy for Carcinoma of the Cervix.
Poster Presentation Society of Gynecologic Oncology: Palm Desert, CA, February 1993.
12. Primary Radiation Therapy for Endometrial Carcinoma: A Case Controlled Study.
American Radium Soc: Aruba, April 1993.
13. Serum Squamous Cell Carcinoma Antigen Levels in Invasive Cervical Cancer: Prediction of Response and Recurrence.
New England Assoc Gynecol Oncol, June 1993.
14. Primary Radiation Therapy for Endometrial Carcinoma: A Case Controlled Study.
New England Assoc Gynecol Oncol, June 1993.
15. D-Dimer and Peritoneal CA-125 Levels as Predictors of Disease Status in Ovarian Carcinoma.
New England Assoc Gynecol Oncol, June 1993.
16. Accuracy of frozen section (intraoperative consultation) diagnosis of ovarian tumors.
Poster Presentation Am Coll Obstetrics and Gynecologists: Orlando, FL, May 1994.
Poster Presentation New England Assoc Gynecol Oncol, June 1994.
17. Serial serum CA-125 measurement for evaluation of recurrence in patients with endometrial carcinoma.
Poster Presentation Am Coll Obstetrics and Gynecologists: Orlando, FL May 1994.
New England Assoc Gynecol Oncol, June 1994.
18. Selective Cytoprotection from the Cytotoxicity of Cyclophosphamide © and Cisplatin (P) +/- Amifostine (A): A Randomized Trial in patients with Advanced Epithelial Ovarian Cancer.
Oral presentation Society of Gynecologic Oncology: San Francisco, CA, February 1995.

PRESENTATIONS: SCIENTIFIC MEETINGS (Con't)

19. A Phase II Trial of Prolonged Oral Etoposide as Second Line Therapy for Advanced and Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study. Poster presentation Am Society Clinical Oncology: Los Angeles, CA, May 1995.
20. Prolonged oral etoposide as second line therapy for platinum resistant (PlatR) and platinum sensitive (PlatS) ovarian carcinoma: A Gynecologic Oncology Group Study. Oral presentation Am Society Clinical Oncology: Philadelphia, PA, May 1996.
21. Ethylol (amifostine) protects against cumulative cisplatin toxicities. Poster presentation Am Society Clinical Oncology: Philadelphia, PA, May 1996.
22. Is positive emission tomography (PET) useful in evaluating disease status when computerized tomography is negative? A surgico-pathologic evaluation in cervical, ovarian and peritoneal carcinoma. New England Assoc Gynecol Oncol, June 1996.
23. Ethylol (amifostine) protects against cumulative platinum toxicities. 14th Chemotherapy Foundation Symposium, NY, NY, 11/6/96.
24. Paclitaxel and cisplatin as first line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group (GOG) study. Poster presentation Am Society Clinical Oncology: Denver, CO, May 1997.
25. Rose P, Bundy B, Thigpen T, Deppe G, Maiman M, Clarke-Pearson D, Watkins E, Insalaco S. Significant preliminary results of a phase III randomized study of concomitant chemoradiation with hydroxyurea vs hydroxyurea, 5-FU infusion and bolus cisplatin (HFC) vs weekly cisplatin in advanced cervical cancer, A GOG study. Oral Plenary Session, Society of Gynecologic Oncologists, Orlando, FL, February 1998.
26. Rose PG, Blessing JA, Soper J, Barter JF. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: A Gynecologic Oncology Group (GOG) study. Poster Presentation, Society of Gynecologic Oncologists, Orlando, FL, February 1998.
27. Rose PG, Blessing JA, Fowler WC, Waggoner S. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group (GOG) study. Poster Presentation Society of Gynecologic Oncologist, Orlando, FL, February 1998.
28. Rose PG, Connelly R, Edinger M, Rodriguez M. Tumor cell autocrine motility factor receptor (AMF-R) expression in ovarian cancer: A potential target for gene therapy. Poster Presentation, Society of Gynecologic Oncologists, Orlando, FL, February 1998.
29. Rodriguez M, Connelly R, Liu D, Edinger M, Rose PG. Insulin like growth factor receptor (IGF-IR) expression in two established ovarian cancer cell lines: A potential in vivo model for gene therapy. Poster Presentation, Society of Gynecologic Oncologists, Orlando, FL, February 1998.

PRESENTATIONS: SCIENTIFIC MEETINGS (Con't)

30. Rose P, Bundy B, Thigpen T, Deppe G, Maiman M, Clarke-Pearson D, Watkins E, Insalaco S. Significant preliminary results of a phase III randomized study of concomitant chemoradiation with hydroxyurea vs hydroxyurea, 5-FU infusion and bolus cisplatin (HFC) vs weekly cisplatin in advanced cervical cancer. A GOG study. Oral Presentation, American Society of Clinical Oncology, Los Angeles CA, May 19, 1998.
31. Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW, Miraldi F. Positive Emission Tomography (PET) for Evaluating Paraortic Nodal Metastasis in Locally Advanced Cervical Cancer Prior to Surgical Staging: A Surgico-Pathologic Study. New England Assoc Gynecol Oncol, June 1998.
32. Rose PG, Fusco N, Fluellen L, Gordan N, Rodriguez M. A Phase II Study of Weekly 72-Hour Topotecan Infusion in Patients with Platin Resistant and Paclitaxel Resistant Ovarian Carcinoma. New England Assoc Gynecol Oncol, June 1998.
33. Rose PG, Rodriguez M, Waggoner S, Greer BE, Horowitz IR, Fowler JM, McGuire WP. A Phase I Study of Paclitaxel, Carboplatin and Increasing Doses of Prolonged Oral Etoposide in Ovarian, Peritoneal, and Tubal Carcinoma: A Gynecologic Oncology Group study. Poster Presentation, Society of Gynecologic Oncologists, San Francisco, CA, March 1999.
34. Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW, Miraldi F. Positive Emission Tomography (PET) for Evaluating Paraortic Nodal Metastasis in Locally Advanced Cervical Cancer Prior to Surgical Staging: A Surgico-Pathologic Study. Poster Presentation, Society of Gynecologic Oncologists, Sand Francisco, CA, March 1999.
35. Rose PG, Blessing JA, Gershenson DM, McGhee R. Paclitaxel and cisplatin as first line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group (GOG) study. Poster Presentation, Society of Gynecologic Oncologists, San Francisco, CA, March 1999.
36. Rose P, Gordon AN, Granai CO, Hainsworth J, Weisman C, Lopez A, Kosty M, Peters WA, Malfetano J, Malviya V, Del Prete SA, Moore M, Wolin E, Goldberg D, Feherenbacher L, Yee SJ, Orr J, Garfield D, Rosales R, Sharpington T. Interim Analysis of a Non-comparative, Multicenter Study of Doxil/Caelyx in the Treatment of Patients with Refractory Ovarian Cancer. Poster Presentation, Am Soc Clin Oncol, Atlanta, GA, May 1999.
37. Rose PG, Gordon NH, Fusco N, Fluellen L, Rodriguez M, Ingalls ST, Hoppel CL. Pharmacokinetic Findings in a Phase II Study of Weekly 72 Hour Topotecan Infusion in Patients with Platin Resistant and Paclitaxel Resistant Ovarian Carcinoma. New England Assoc Gynecol Oncol, June 1999.
38. Rose PG. Skin Bridge Recurrences in Vulvar Cancer: Frequency and Management. New England Assoc Gynecol Oncol, June 1999.
39. Rose PG, Lapas P. Analysis of the Cost-Effectiveness of Cisplatin-Based Chemoradiation in Cervical Cancer: Implications from Five Randomized Trials. New England Assoc Gynecol Oncol, June 1999.

PRESENTATIONS: SCIENTIFIC MEETINGS (Con't)

40. Rose PG, Skin Bridge Recurrences in Vulvar Cancer: Frequency and Management. Poster presentation Society of Gynecol Oncol, San Diego 2/7/2000.
41. Rose PG, Greer BE, Markman M, Horowitz IR, Fusco N, McGuire WP. A phase I study of paclitaxel, carboplatin, and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: A Gynecologic Oncology Group study. Am Soc Clin Oncol, New Orleans, LA, May 2000.
42. Rose PG, Greer BE, Walker J, Fusco N, McGuire WP. A Phase I study of oral etoposide and liposomal doxorubicin in ovarian, peritoneal and tubal carcinoma: A Gynecologic Oncology Group Study. Poster Presentation Society Gynecologic Oncology March 2001.
43. Connelly RW, Chernicky CL, Yi L, Tan H, Rose PG, Rodriguez M, Ilan J. Insulin like growth factor I (IGF-I) protects human ovarian cancer cells from Cisplatin induced cell proliferation in vitro. Poster Presentation Society Gynecologic Oncology March 2001.
44. Activity of Gemcitabine/Cisplatin in Gemcitabine resistant gynecologic cancers. New England Assoc Gynecol Oncol, June 2001.
45. Liposomal Doxorubicin in recurrent ovarian, peritoneal and tubal carcinoma. A retrospective comparative study of single agent dosages. New England Assoc Gynecol Oncol, June 2001.
46. Markman M, Rose PG, Kennedy A, Webster K, Zanotti K, Belinson J. Phase 2 trial of carboplatin, paclitaxel and irinotecan in ovarian cancer and primary cancer of the peritoneum. 19th Chemotherapy Foundation Symposium, NY, NY, 11/2001.
47. Rose PG, Mossbrugger K, Fusco N, Smrekar M, Eaton S, Rodriguez M. Gemcitabine reverses cisplatin resistance: Demonstration of activity in platinum and multi-drug resistant ovarian and peritoneal carcinoma. Oral Presentation Society Gynecologic Oncology March 16-20, 2002.
48. Rose PG, Markman M, Bell J. A phase I study of sequential prolonged oral topotecan and prolonged oral etoposide as second line therapy in ovarian, peritoneal or tubal carcinoma. Poster Presentation Society Gynecologic Oncology March 16-20, 2002.
49. Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, Moore DH. A phase II study of docetaxel in paclitaxel resistant ovarian and peritoneal carcinoma. A Gynecologic Oncology Group Study. Poster Presentation Society Gynecologic Oncology March 16-20, 2002.
50. Connelly RW, Rose PG. Insulin like growth factor-1 (IGF-1) upregulation of heat shock protein 27KDA(HSP27): A potential mechanism of cisplatin resistance in a human ovarian cancer cell line. Poster Presentation Society Gynecologic Oncology March 16-20, 2002.
51. Rose PG, Nerenstone S, Brady M, Clarke-Pearson D, Olt G, Rubin SC, Moore DH. Phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a gynecologic oncology group study. Oral Presentation, American Society of Clinical Oncology, Orlando, FL, May 21, 2002.

PRESENTATIONS: INVITED EXTRA-MURAL LECTURES

1. Gestational Trophoblastic Disease. Grand Rounds, Dept of Obstetrics and Gynecology, State University of New York Health Science Center. Buffalo, NY, March 1988.
2. Tumor Markers in Gynecologic Cancer. Grand Rounds, Dept of Obstetrics and Gynecology, Long Island Jewish Hospital, December 1999.
3. Ovarian Cancer: Risk Factors, Screening and Evaluation of the Pelvic Mass. Grand Rounds, Dept of Obstetrics and Gynecology, William Beaumont Hospital, Detroit, MI, January 1991.
4. Gynecologic Sarcomas. Grand Rounds, Dept of Obstetrics and Gynecology, William Beaumont Hospital, Detroit, MI, January 1991.
5. Endometrial Carcinoma: Recent Advances. Central OB/Gyn Travel Club. Wolfboro, NH, 9/20/92.
6. Gynecologic Sarcomas. Central OB/Gyn Travel Club. Wolfboro, NH, 9/21/92.
7. Endometrial Cancer: The role of Lymph Node Dissection. Cleveland Society of Obstetrics and Gynecology, Cleveland, OH, 3/16/94.
8. Endometrial Carcinoma: Recent Advances. State University of New York Health Science Center. Syracuse, NY, March 18, 1994.
9. Pediatric Ovarian Tumors. Buffalo Obstetric and Gynecology society and Buffalo Pediatric Society, Buffalo, NY, 1/10/95.
10. Preoperative Evaluation and Postoperative Management. Grand Rounds, Dept of Obstetrics and Gynecology, State University of New York Health Science Center. Buffalo, NY, 1/11/95.
11. Ovarian Cancer: Risk Factors, Screening and Evaluation of the Pelvic Mass. Cleveland Society of Obstetrics and Gynecology, Cleveland, OH, 3/15/95.
12. Ethyol protects against cumulative cisplatin toxicities. Second International Ethyol meeting. Philadelphia, PA, 5/16/96.
13. Ovarian Cancer: Grand Rounds, Mt. Sinai Department of OR Nursing, Mt. Sinai Hospital, Cleveland, OH, 8/31/95.
14. The Role of Amifostine in Chemotherapy for Advanced Ovarian Carcinoma. Applications of Amifostine in Cancer Treatment, West Palm Beach, FL, 12/9/95.
15. Role of Amifostine in Chemotherapy for Advanced Ovarian Carcinoma. Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN, 5/24/96.
16. Ovarian Cancer: Risk Factors, Screening and Evaluation of the Pelvic Mass. Grand Rounds, Dept. of Obstetrics and Gynecology, Henry Ford Hospital, Detroit, MI, 5/30/96.
17. Screening for cancer in the menopausal patient. North American Menopause Society. Chicago, IL, 9/20/96

PRESENTATIONS: INVITED EXTRA-MURAL LECTURES(Con't)

18. Protection against chemotherapy induced toxicities. State University of New York Health Science Center. Syracuse, NY, 11/21/96.
19. Ovarian Cancer: Risk Factors, Screening and Evaluation of the Pelvic Mass. Univ Texas Southwestern Medical Center, Dallas, TX, 2/26/97.
20. Chemotherapy Cytoprotection. Creighton University, Omaha, NE, 4/22/97.
21. Ovarian Cancer: Risk Factors, Screening and Evaluation of the Pelvic Mass. Univ Nebraska Medical Center, Omaha, NE, 5/8/97.
22. Chemotherapy Cytoprotection. The Cancer Center of Boston, Boston, MA, 6/12/97.
23. Hereditary Ovarian Cancer. Central OB/Gyn Travel Club. Cleveland, OH, 9/20/97.
24. Chemotherapy Cytoprotection. Roswell Park Cancer Center, Buffalo, NY, 10/16/97.
25. Chemotherapy Cytoprotection for Advanced Ovarian Cancer. Yale-Division of Gynecologic Oncology, New Haven, CT, 11/13/97.
26. Chemotherapy Cytoprotection for Advanced Ovarian Cancer. State University of New York Health Science Center-Downstate. Brooklyn, NY, 12/15/97.
27. Chemotherapy Cytoprotection. Montifiore Medical Center. Bronx, NY, 12/15/97.
28. Oral Chemotherapy. Baltimore, MD, 6/2/98.
29. Ovarian Cancer – Second Line Therapy. Massachusetts General Hospital. Boston, MA, 9/17/98.
30. Oral Topotecan. Hycamptin Worldwide Investigators Meeting, Montreaux, Switzerland, 10/3/98.
31. Ovarian Cancer. North Shore University Hospital, Manhasset, NY, 10/21/98.
32. Ovarian Cancer. University of Pittsburgh. Pittsburgh, PA, 10/27/98.
33. Selective Cytoprotection from the Cytotoxicity of Cyclophosphamide (C) and Cisplatin (P) +/- Amifostine (A): A Randomized Trial in patients with Advanced Epithelial Ovarian Cancer. Invited Speaker, Korea, 10/31/98.
34. Concomitant use of radiation and chemotherapy is standard of care for locally advanced cervical cancer. Controversies in Gynecologic Cancer, Mercy Medical Center, Baltimore, MD, 11/14/98.
35. Second look surgery helps guide subsequent therapy in ovarian cancer. Controversies in Gynecologic Cancer, Mercy Medical Center, Baltimore, MD, 11/14/98.
37. Ovarian Cancer. Akron General Hospital. Akron, OH, 11/24/98.

PRESENTATIONS: INVITED EXTRA-MURAL LECTURES(Con't)

38. Endometrial Carcinoma: Issues for the General Gynecologist. Cleveland Society of Obstetrics and Gynecology, Cleveland, OH, 1/20/99.
39. Ovarian Cancer – Second Line Therapy. Assoc Chicago Gynecol Oncol, 2/23/99.
40. Liposomal Doxorubicin in Ovarian Cancer. Munich, Germany, 5/8/99.
41. Concurrent Cisplatin Chemoradiation for Locally Advanced Cervical Cancer and High Risk Early Stage Disease. David and Lenore Katz Memorial Lectureship. University of Pittsburgh, Magee-Womens Hospital. Pittsburgh, PA, 5/25/99.
42. Concurrent Weekly Cisplatin Chemoradiation is the Treatment of Choice for Locally Advanced Cervical Cancer. Controversies of Cancer of the Cervix or Corpus. GOG Phoenix Symposium, 7/22/99.
43. Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer. Controversies in the Management of Gynecologic Malignancies. Washington, DC, September 9-10, 1999.
44. Surgical Management of Primary and Recurrent Disease, Advanced Ovarian Cancer Consensus Conference. Rome, Italy, 9/28/99.
45. Chemoirradiation for Cervical Carcinoma, Where Do We Stand Now? The Flemish Gynecologic Oncology group and the Belgian Society of Obstetrics and Gynecology, Keerbregen, Belgium 10/2/99.
46. Cisplatin Based Chemoradiation for Locally Advanced and High Risk Cervical Cancer. 23rd Cancer Symposium Scripps Memorial Hospital Center, LaJolla, CA, 10/15/99.
47. New Standards of Care for the Treatment of Gynecologic Malignancies. ASCO Fall Educational Conference, San Francisco, CA, 11/7/99.
48. Concurrent Radiotherapy and Chemotherapy vs Radiotherapy Alone for Cervical Cancer. Superior School of Oncology and Biomedical Sciences, Genoa, Italy, 1/11/99.
49. Advances in Gynecologic Chemotherapy. Duke University, Durham, NC, 12/8/99.
50. Second Line Therapy for Ovarian Cancer. Ovarian Cancer Survivors Seminar, Society of Gynecol Oncol, San Diego, CA, 2/5/2000.
51. Advanced cervical cancer: Chemoradiation and chemotherapy for metastatic disease. Mercy Hospital, Miami, FL. March 10, 2000.
52. Advanced cervical cancer: Chemoradiation and chemotherapy for metastatic disease. University of Miami, Sylvester Cancer Center, Miami, FL. March 10, 2000.
53. Ovarian Carcinoma, Orlando, FL. March 23-25, 2000.
54. Chemoradiation for Cervical Cancer, Mayo Clinic, Jacksonville, FL. March 30, 2000.

PRESENTATIONS: INVITED EXTRA-MURAL LECTURES (Con't)

55. When to refer to a gynecologic oncologist? Basic and advanced colposcopy course. Quail Hollow, Painesville, OH. May 13, 2000.
55. Chemotherapy and radiation therapy for cervical cancer. Am Soc Clin Oncol, New Orleans, LA, May 20-21, 2000.
56. Cervical cancer: An overview and recent advances. University of Vermont, Burlington, VT, June 13, 2000.
57. Cancer Treatment Update: Highlights of ASCO 2000. Department of Veteran Affairs VISN16. Birmingham, AL, June 22, 2000.
58. First line chemotherapy and second-line chemotherapy for ovarian cancer. Carolinas Medical Center, Charlotte, NC, August 17, 2000.
59. Gynecologic Cancer Symposium, Holy Cross Hospital, Bethesda, MD, September 5-6, 2000.
60. Ovarian Cancer, Harbor UCLA, Torrance, CA September 13, 2000.
61. Ovarian Cancer, City of Hope, Santa Monica, CA September 13, 2000.
62. Recurrent Ovarian Cancer Management Options, Grossmont Hospital, LaMesa, CA September 14, 2000.
63. Recurrent Ovarian Cancer, VA Medical Center, LaJolla, CA September 15, 2000
64. Phase III Randomized Trial of Doxil vs. Topotecan in Refractory Ovarian Cancer, Atlanta, GA September 23, 2000.
65. Randomized trial of Caelyx vs. Topotecan, Stockholm, Sweden, Sept 29-30, 2000.
66. Chemotherapy: Indications of use and emerging protocols. Northeastern Ohio Universities College of Medicine. Rootstown, OH November 1, 2000.
67. First line chemotherapy: Taxane combinations. European School of Oncology Postgraduate Course "Ovarian Cancer" Athens, Greece November 3, 2000.
68. Platinum resistant disease: Single Agents. European School of Oncology Postgraduate Course "Ovarian Cancer" Athens, Greece November 4, 2000.
69. Ovarian Cancer: Conference on Surgical management of Ovarian Cancer. Washington, DC November 14, 2000.
70. Overview of 2nd line treatment in Taxane failure ovarian cancer patients. Vancouver, BC November 28, 2000.
71. Future of Gynecologic Oncology: Has chemoradiation in cervical cancer improved the survival for patients with cervical cancer? Oslo, Norway December 8, 2000.

72. Future of Gynecologic Oncology: The final results of a randomized study between Topotecan and Caelyx in recurrent ovarian cancer. Oslo, Norway December 8, 2000.
73. Advances in the treatment of cervical cancer. International Network for Cancer Treatment and Research. Brussels, Belgium April 20, 2001.
74. Cooperative Clinical Trials in Gynecologic Oncology. U of Minnesota Consensus Conference, Red Wing , MN May 4, 2001.
75. Management of Ovarian Cancer: A Multidisciplinary Approach. Quebec, Canada September 6-9, 2001.
76. Advances in the management of cervical cancer. Comprehensive Gynecologic Oncology: Roswell Park Cancer Institute, Buffalo, NY Sept 29, 2001.
77. Advances in Cancer of the Cervix. Mt. Sinai Hospital, University of Toronto, Toronto, Ontario Canada, October 26,2001.
78. Indications for Chemotherapy for Ovarian and Cervical Cancer. University of Virginia. Charlottesville, VA, April 10, 2002.
79. Indications for Chemotherapy for Ovarian Cancer. Medical College of Virginia, Richmond, VA April 11, 2002.
80. Chemoradiation: New Perspectives. 2nd International Conference on Cervical Cancer Houston, TX, April 13, 2002.
81. Ovarian cancer chemotherapy. Memphis, TN September 5, 2002.
82. Ovarian cancer identification & management of the high risk patient. St. Elizabeth Hospital, Youngstown, OH September 19-20, 2002.
83. Screening and early detection in gynecologic cancer, including transvaginal, color flow doppler and tumor markers, prophylactic gynecologic surgery. Providence Cancer Institute, 8th Annual Jaffar Strategies for prevention and a cure: Gynecologic Cancer. Detroit, MI September 27, 2002.
84. Management of Cervical Cancer. Ohio Society of Cytology Fall Mini-Seminar, Euclid Hospital-Cleveland Clinic Health System, Euclid OH October 12, 2002.
85. Advances in chemotherapy strategies for ovarian cancer. Ohio State University, Columbus, OH, October 18, 2002.
86. Ovarian Cancer and GOG Initiatives. University of Virginia, Charlotte, VA, April 12, 2003.
87. Ovarian Cancer: Small but Continued Improvement. Hervy Averette Ovarian Cancer Lectureship, Miami, FL, August 28, 2003.

PRESENTATIONS: INVITED INTRA-MURAL LECTURES (Partial list)

1. Gynecologic Health: A Pattern for Preventive Care Ireland Cancer Center Conference: Fashion with a Flair for Life. Cleveland, OH, 4/29/95.
2. Surgery for Gynecologic Malignancies, Ireland Cancer Center Conference: Oncology Nursing Society, 9/22/95.
3. What are the warning signs for cervical and ovarian cancer. Community Program Landerbrook, Cleveland, OH, 10/17/96.
4. Surgery for Ovarian Cancer: Grand Rounds Dept. of Surgery, UH, 10/28/95.
5. Endometrial Carcinoma: Recent Advances. Grand Rounds, Dept. of OB/Gyn, UH.
6. Vulvar Cancer Recent Changes, Grand Rounds, Dept. of OB/Gyn, UH.
7. Ovarian Cancer: Risk Factors, Screening and Evaluation of the Pelvic Mass. Grand Rounds, Dept. of Ob/Gyn, UH.
8. Gynecologic Cancers: Risk factors and implications for screening. Dept. of Family Medicine, UH, 6/4/96.
9. Screening for Upper Genital Tract Cancers. Understanding Common Female Cancers, Cleveland, OH, 4/2 and 4/22/97.
10. Screening for Gynecologic Cancers. Gynecology for the Non-Gynecologist. UH, Cleveland, OH, 9/26/97 and 6/5/98.
11. Ovarian Cancer. Dept. of Pathology, UH, 10/27/97.
12. 1995, 1996, 1997, 1998, 1999. Pathophysiology of Gynecologic Cancers: CWRU Medical School 2nd year class.
13. Ovarian Cancer. Grand Rounds, Dept. of OB/Gyn, UH 12/18/97.
14. Cervical Cancer. OR Nursing, Grand Rounds, UH, 1/98.
15. Ovarian Cancer. Grand Rounds, Dept. of OB/Gyn, Mt. Sinai, 1/98.
16. Evaluation of the Abnormal Pap Smear: Evaluation and Management of Cancer for the Primary Practitioner, Ireland Cancer Center Program, Cleveland Hilton 3/14/98, Geauga Hospital 4/7/98, Southwest General Hospital, 5/6/98.
17. Ovarian Cancer. Grand Rounds, Dept. of OB/Gyn Metro Health Medical Center, 10/29/98.
18. Uterine Cancer. Ohio University Osteopathic Medicine Teleconference, 11/18/98.
19. Concurrent Chemoradiation for Locally Advanced Cervical Cancer. Grand Rounds, Dept. of OB/Gyn, UH, 9/8/99.

PRESENTATIONS: INVITED INTRA-MURAL LECTURES (Con't)

20. Cervical Cancer. Grand Rounds, Cancer Center Metro Health Medical Center, 6/8/2000.
21. Advances in the management of cervical cancer. Cleveland Ob/Gyn Society, Cleveland, Oh, November 7, 2001.
22. Be your own lifeguard with cancer check-ups. Embracing Wellness: A forum on women's health. American Cancer Society. Cleveland, OH, November 16, 2001.